First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.
ABILD partnership aims at enhancing health innovation projects to comprehend care gaps in diagnosis, treatment, and access for Albertans with progressive fibrosing ILD.
Boehringer Ingelheim employees across the U.S. are out in their communities making a difference to help improve the lives of those who have been impacted by the coronavirus.
Improving primary care in Alberta’s Indigenous Populations. Read more about ABIC, an example of how delivering innovative solutions can improve health equity.
Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population
Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population
Boehringer Ingelheim Canada joins forces with top institutions in Quebec to foster excellence in healthcare. Find out more about our partnering activities.